Based on the clinical efficacy data and in vitro drug sensitivity data, we speculate that the effectiveness of crizotinib against MET fusion is parallel to that for the MET exon 14 skipping mutation, and may even be more superior in NSCLC. The gene discussed is MET; the disease is non-small cell lung carcinoma.